January 10, 2023 -- Mayo Clinic Laboratories and Helix on Tuesday announced a strategic collaboration that will provide biopharma customers access to a comprehensive joint laboratory offering for research and development initiatives across the drug development lifecycle.
The offering will include a full spectrum of testing capabilities that leverages both Helix's suite of next generation sequencing capabilities and Mayo Clinic Laboratories' portfolio of more than 3,800 tests and pathology services.
Mayo Clinic Laboratories said that with Helix it will provide biopharma customers with full end-to-end laboratory testing support.
Financial and other terms of the collaboration were not disclosed.
"In addition to the testing knowledge, our Mayo Clinic physicians and scientists are available for consultation during this process to provide their expertise and guidance," Dr. William Morice II, president and CEO of Mayo Clinic Laboratories, said in a statement.
The collaboration builds upon an existing relationship between the two organizations. Helix collaborates with the Mayo Clinic Center for Individualized Medicine Tapestry program, which is a 100,000-participant population genomics program. All participants in this program are sequenced using Helix's Exome+ assay at the firm's clinical laboratory in San Diego.